Kalaris Therapeutics (KLRS) Competitors

$4.92 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$5.10 +0.18 (+3.56%)

As of 05/22/2026 07:59 PM Eastern

KLRS vs. KMDA, FULC, ZURA, PRTC, and EOLS

Should you buy Kalaris Therapeutics stock or one of its competitors? MarketBeat compares Kalaris Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kalaris Therapeutics include Kamada (KMDA), Fulcrum Therapeutics (FULC), Zura Bio (ZURA), PureTech Health (PRTC), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry.

How does Kalaris Therapeutics compare to Kamada?

Kamada (NASDAQ:KMDA) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Kamada has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market.

In the previous week, Kamada and Kamada both had 6 articles in the media. Kalaris Therapeutics' average media sentiment score of 0.70 beat Kamada's score of -0.53 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Kalaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

20.4% of Kamada shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kamada presently has a consensus price target of $12.00, indicating a potential upside of 53.26%. Kalaris Therapeutics has a consensus price target of $15.60, indicating a potential upside of 217.07%. Given Kalaris Therapeutics' higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Kamada has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.50	$20.20M	$0.35	22.37
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Kamada has a net margin of 11.21% compared to Kalaris Therapeutics' net margin of 0.00%. Kamada's return on equity of 7.73% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

Summary

Kamada beats Kalaris Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Fulcrum Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Kalaris Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.02, indicating that its stock price is 202% more volatile than the broader market.

Kalaris Therapeutics currently has a consensus target price of $15.60, suggesting a potential upside of 217.07%. Fulcrum Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 189.19%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kalaris Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Fulcrum Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Fulcrum Therapeutics' return on equity of -27.80% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

In the previous week, Kalaris Therapeutics had 5 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 1 mentions for Fulcrum Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.70 beat Fulcrum Therapeutics' score of -0.50 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Kalaris Therapeutics has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Fulcrum Therapeutics	$80M	5.47	-$74.88M	-$1.15	N/A

Summary

Kalaris Therapeutics beats Fulcrum Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Zura Bio?

Kalaris Therapeutics (NASDAQ:KLRS) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Zura Bio's return on equity of -55.74% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Zura Bio	N/A	-55.74%	-48.07%

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 14.2% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kalaris Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market. Comparatively, Zura Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

Kalaris Therapeutics currently has a consensus price target of $15.60, suggesting a potential upside of 217.07%. Zura Bio has a consensus price target of $10.75, suggesting a potential upside of 146.56%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Kalaris Therapeutics is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Zura Bio is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

In the previous week, Kalaris Therapeutics had 4 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 2 mentions for Zura Bio. Kalaris Therapeutics' average media sentiment score of 0.70 beat Zura Bio's score of 0.05 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kalaris Therapeutics beats Zura Bio on 11 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, Kalaris Therapeutics had 6 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 0 mentions for PureTech Health. Kalaris Therapeutics' average media sentiment score of 0.70 beat PureTech Health's score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Neutral
Kalaris Therapeutics	Positive

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PureTech Health's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Kalaris Therapeutics	N/A	-72.78%	-43.49%

Kalaris Therapeutics has a consensus price target of $15.60, suggesting a potential upside of 217.07%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Kalaris Therapeutics has lower revenue, but higher earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

PureTech Health has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market.

Summary

Kalaris Therapeutics beats PureTech Health on 9 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Evolus?

Kalaris Therapeutics (NASDAQ:KLRS) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Kalaris Therapeutics has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market. Comparatively, Evolus has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kalaris Therapeutics has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Evolus	$297.18M	1.35	-$51.64M	-$0.67	N/A

In the previous week, Kalaris Therapeutics had 4 more articles in the media than Evolus. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 2 mentions for Evolus. Kalaris Therapeutics' average media sentiment score of 0.70 beat Evolus' score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kalaris Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Evolus	-14.39%	N/A	-19.03%

Kalaris Therapeutics presently has a consensus target price of $15.60, suggesting a potential upside of 217.07%. Evolus has a consensus target price of $16.00, suggesting a potential upside of 162.73%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Kalaris Therapeutics beats Evolus on 10 of the 16 factors compared between the two stocks.

Get Kalaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRS vs. The Competition

Export

Metric	Kalaris Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$117.06M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-2.29	18.74	21.21	25.65
Price / Sales	N/A	323.98	554.38	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	1.71	7.09	10.37	7.14
Net Income	-$43.44M	$24.45M	$3.57B	$335.98M
7 Day Performance	4.66%	6.38%	6.40%	4.15%
1 Month Performance	-19.48%	2.43%	3.53%	2.54%
1 Year Performance	76.34%	62.98%	34.04%	35.06%

Kalaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRS Kalaris Therapeutics	4.2755 of 5 stars	$4.92 flat	$15.60 +217.1%	+76.3%	$117.06M	N/A	N/A	110	Positive News Analyst Downgrade Gap Down
KMDA Kamada	4.8853 of 5 stars	$7.82 -2.5%	$12.00 +53.5%	+18.1%	$449.73M	$180.46M	22.34	360	Analyst Downgrade
FULC Fulcrum Therapeutics	1.6065 of 5 stars	$6.74 -5.2%	$19.00 +181.9%	+2.0%	$448.95M	$80M	N/A	100
ZURA Zura Bio	2.98 of 5 stars	$4.63 -4.1%	$10.75 +132.2%	+327.5%	$439.86M	N/A	N/A	3
PRTC PureTech Health	0.1685 of 5 stars	$17.85 -0.6%	N/A	N/A	$434.47M	$4.66M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRS) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. KMDA, FULC, ZURA, PRTC, and EOLS

How does Kalaris Therapeutics compare to Kamada?

Summary

How does Kalaris Therapeutics compare to Fulcrum Therapeutics?

Summary

How does Kalaris Therapeutics compare to Zura Bio?

Summary

How does Kalaris Therapeutics compare to PureTech Health?

Summary

How does Kalaris Therapeutics compare to Evolus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. KMDA, FULC, ZURA, PRTC, and EOLS

How does Kalaris Therapeutics compare to Kamada?

Which has more volatility & risk, KMDA or KLRS?

Does the media refer more to KMDA or KLRS?

Do institutionals & insiders believe in KMDA or KLRS?

Do analysts rate KMDA or KLRS?

Which has preferable valuation and earnings, KMDA or KLRS?

Is KMDA or KLRS more profitable?

Summary

How does Kalaris Therapeutics compare to Fulcrum Therapeutics?

Which has more risk and volatility, KLRS or FULC?

Do analysts recommend KLRS or FULC?

Do insiders & institutionals believe in KLRS or FULC?

Is KLRS or FULC more profitable?

Does the media favor KLRS or FULC?

Which has higher earnings & valuation, KLRS or FULC?

Summary

How does Kalaris Therapeutics compare to Zura Bio?

Is KLRS or ZURA more profitable?

Do institutionals and insiders hold more shares of KLRS or ZURA?

Which has more risk & volatility, KLRS or ZURA?

Do analysts prefer KLRS or ZURA?

Which has better valuation & earnings, KLRS or ZURA?

Does the media prefer KLRS or ZURA?

Summary

How does Kalaris Therapeutics compare to PureTech Health?

Does the media refer more to PRTC or KLRS?

Do insiders & institutionals hold more shares of PRTC or KLRS?

Is PRTC or KLRS more profitable?

Do analysts rate PRTC or KLRS?

Which has higher valuation and earnings, PRTC or KLRS?

Which has more volatility and risk, PRTC or KLRS?

Summary

How does Kalaris Therapeutics compare to Evolus?

Which has more risk & volatility, KLRS or EOLS?

Do institutionals and insiders believe in KLRS or EOLS?

Which has better earnings & valuation, KLRS or EOLS?

Does the media favor KLRS or EOLS?

Is KLRS or EOLS more profitable?

Do analysts rate KLRS or EOLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools